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ABSTRACT 
Purpose: 
Broadening access to genomic testing and counselling will be necessary to 
realise the benefits of personalised healthcare. This study aimed to 
assess the feasibility of delivering a standardised genomic care model for 
inherited retinal dystrophy (IRD) and of using selected measures to 
quantify its impact on patients.  
Methods: 
A pre-post prospective cohort study recruited 98 patients affected by IRD 
to receive standardised multidisciplinary care. A checklist was used to 
assess the fidelity of the care process. Patient-reported outcome measures 
– the Genetic Counselling Outcome Scale (GCOS-24), ICEpop CAPability 
measure for Adults (ICECAP-A), and the EuroQol 5-dimension questionnaire 
(EQ-5D) – and a resource-use questionnaire were administered to 
investigate rates of missingness, ceiling effects, and changes over time.   
Results: 
The care model was delivered consistently. Higher rates of missingness 
were found for the genetic-specific measure (GCOS-24). Considerable 
ceiling effects were observed for the generic measure (EQ-5D). The ICECAP-
A yielded less missing data, without significant ceiling effects. It was 
feasible to use telephone interviews for follow-up data collection. 
Conclusion: 
The study highlighted challenges and solutions associated with efforts to 
standardise genomic care for IRD. The study identified appropriate methods 
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for a future definitive study to assess the clinical and cost-
effectiveness of the care model. 
Key words 
Clinical genetics service; Care model; Feasibility; Genomic; Outcomes 
INTRODUCTION 
High-throughput molecular approaches have rapidly moved from the research 
arena into direct clinical care and are a powerful demonstration of the 
implementation of biomedical research. Such approaches have enormous 
potential - across all aspects of medicine - to improve the effectiveness 
of molecular diagnosis and increase the power and potential of 
personalised approaches to healthcare. Demonstrable impacts on diagnostic 
rates and treatment have already been shown across a broad range of 
specialties.1–4 
In order to achieve widespread implementation of genomic care, it will be 
necessary to alter care pathways to incorporate early genomic testing and 
then expand the delivery of genetic and genomic care beyond clinical 
genetics and into mainstream clinical specialties.5–7 A recent review of 
genetic service models has suggested that multidisciplinary clinics and 
coordinated services are key to delivering proper care in rare genetic 
disorders.8 Therefore, the delivery of integrated genomic approaches will 
require significant alterations in multidisciplinary workforce planning 
and training.9 Furthermore, since it will inevitably impact upon 
commissioning and payment, there is a compelling need to establish whether 
new working practices are feasible, acceptable to patients and represent 
value-for-money.10  
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Inherited Retinal Dystrophies (IRD) are a major cause of blindness among 
children and working-age adults 11,12 with one in every 3,000 people 
affected.13 IRD are heterogeneous in genetic cause, mode of inheritance and 
phenotypic expression. Currently, there is no effective way of arresting 
or reversing the resultant sight loss, although novel therapeutic 
strategies for certain forms of IRD are in development.14 There are no gold 
standard recommendations for how best to provide genetic ophthalmology 
services for IRD, which can comprise genetic counselling, risk assessment, 
risk communication, genetic testing, information provision and physical 
examination. Up to now, a lack of clear guidelines on how to deliver 
clinical and diagnostic services for IRD has resulted in variation in 
practice across the UK.5,15 Approved genetic-based diagnostic tests for IRD 
have been nationally available for over ten years, but audit data provides 
evidence of geographical inequity of access.15 As an example of a ŧcomplex 
interventionŨ ſone with several interacting componentsƀ16 special 
challenges are raised for evaluators, including how to standardise its 
design and delivery.17 A standardised care model for people with suspected 
IRD could, in theory, enable consistency of service provision to address 
such variations. 
A care model (see Figures 1 and 2) was developed in response to a stated 
need by patients with IRD and as a result of qualitative research which 
explored these needs 18,19 using the Kellogg Logic Model Development Guide.20 
The care model was delivered in multidisciplinary clinics at a single 
regional genetics centre by ophthalmologists (for eye examinations, 
diagnosis and clinical management), genetic counsellors (to provide 
counselling support and convey genetic information), and eye clinic 
liaison officers (to provide further practical and emotional support). 
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Care was provided in multidisciplinary clinics to ensure that: 
consultations were not delayed by the need to refer elsewhere; patients 
did not need to travel to meet with different specialties; and 
communication between specialties was improved (as it could happen face-
to-face in the clinic). 
The aim of this study was to assess the fidelity of delivering the 
standardised care model and the feasibility of using selected measures to 
quantify its impact on patients and healthcare resource use. The study 
would inform a future definitive study to assess the clinical and cost-
effectiveness of the care model. 
<Insert Figure 1> 
<Insert Figure 2> 
PATIENTS AND METHODS 
This study used a pre-post design to understand the potential impact of 
the standardised care model, using selected measures of outcome and 
healthcare resource use.  
Patient population 
The eligible patient population for the study was defined as any adult 
patient accessing the standardised care model in the allocated recruitment 
period (22/11/2013 and 28/11/2014). This population included existing and 
new users of the service. Patients were eligible for inclusion if they 
were referred for a suspected IRD and if they were 18 years or older on 
the date of the clinic. Participants were ineligible for inclusion if 
written informed consent could not be obtained or if they were unable to 
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complete patient reported outcome measures (PROMs) due to learning 
difficulties or insufficient English language skills. Potential study 
participants were identified by a genetic counsellor as eligible for 
recruitment prior to attending the appointment, were sent a study 
information sheet, and then recruited by a researcher based in the 
reception area of the clinic whose purpose was to obtain informed consent 
and administer the PROMs before the patient consultations.  
Fidelity 
In a typical appointment, the patient would see an ophthalmologist, a 
genetic counsellor, and an eye clinic liaison officer. A manual checklist 
was attached to the front of each patient file, which followed the patient 
as they moved between the different specialties. The checklist comprised 
six key areas covering different elements of the consultation process: 
diagnosis & management; provision of clinical information; provision of 
research information; decision making; counselling & communication; and 
offering practical support. Clinicians worked together to provide care in 
these six key areas, which were the appointment deliverables outlined in 
Figure 2. All members of the multidisciplinary team were asked to update 
the checklist after each consultation with a recruited patient as a 
mechanism to confirm the fidelity of delivering a standardised care model. 
Clinicians were asked to record the time spent on each element in the care 
model and whether or not patients were new to the service. Clinicians also 
indicated, using a tick-box, whether or not the patient was provided with 
a personalised follow-up plan.  
Ten appointments were recorded on video and independently assessed 
afterwards to judge whether clinicians adhered to the care model and how 
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accurately the checklist was completed. Clinicians and patients consented 
to being recorded and evaluated. 
Outcome measures 
Three PROMs were administered in this study: the 24-item Genetic 
Counselling Outcome Scale (GCOS-24), the ICEpop CAPability measure 
for Adults (ICECAP-A), and the three-level version of the EuroQol five-
dimensional questionnaire (EQ-5D-3L). Two of the three PROMs, the GCOS-24 
and the ICECAP-A, were identified as suitable by previous qualitative 
research.18,21,22 
The selection of the GCOS-24 was informed by a previous programme of work 
on how to value outcomes of clinical genetics services.21–23 This work 
pointed towards the need for a broader evaluative scope in assessing the 
benefits of clinical genetics services, which, as complex interventions, 
have broader objectives than only change in health status. The GCOS-24 was 
developed and validated to measure the patient benefits from clinical 
genetics services.24 Specifically, the 24-item scale can be used to measure 
changes in ŧempowermentŨ levels for patients who receive genetic 
counselling and/or testing, and captures patient benefits conceptualised 
as perceptions of control, hope for the future, and emotional regulation 
relating to the genetic condition in the family. Responses to GCOS-24 
questions are given on a Likert scale from 1 to 7 (strongly disagree to 
strongly agree) where 4 is a neutral response. A completed GCOS-24 
questionnaire yields scores between 24 and 168, where higher scores are 
preferable. 
The ICECAP-A was identified as a relevant measure specifically in this 
patient population through qualitative face-to-face interviews with 
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patients with IRD.18,19 The ICECAP-A was designed to measure a concept 
called ŧcapabilityŨ for use in economic evaluation.25 Its development was 
theoretically grounded in work by economists who argued that an important 
aspect of outcome measurement should focus on what people are capable of 
doing, as opposed to only health status.26 The ICECAP-A covers five domains 
(attachment, stability, achievement, enjoyment, and autonomy) and its UK 
scoring tariff can be used to convert responses to scores between 0 and 1, 
where 0 represents ŧno capabilityŨ and ɨ represents ŧfull capabilityŨ.27 
ICECAP-A domains have four levels, where higher levels indicate greater 
capability for a given domain. The ICECAP-A has exhibited desirable 
validity and acceptability in the general population.28 Qualitative work 
suggested that the concept of ŧautonomyŨ is particularly important for 
people diagnosed with inherited eye conditions,18 which is included as a 
domain in the ICECAP-A measure. Measures of capability could, in theory, 
also capture the impact of being able to make an informed decision which 
has been identified as a core goal for clinical genetics services.23 
The EuroQol EQ-5D (3 level version) was included as it is a widely-used, 
validated measure of health status recommended for use to capture benefit 
in cost-effectiveness analysis.29,30 The EQ-5D-3L covers five domains 
(mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) and completion of the EQ-5D yields a descriptive 
health state. The EQ-5D UK scoring tariff can then be used to convert 
health states to ŧutilityŨ scores between -0.594 and 1, where negative 
scores are considered ŧworse than deathŨ and ɨ represents ŧfull healthŨ.31 
Previous work has suggested that health status is unlikely to be improved 
by clinical genetic services where patients cannot be offered an active 
treatment.23 However, it was still considered important to include this 
9 
 
measure to provide empirical evidence on whether an intervention for IRD 
could have an impact on health status.     
Resource use 
A resource use questionnaire was used to elicit the services that patients 
accessed over the month prior to interview, and the numbers of times each 
of these services were accessed. The questionnaire was designed for 
assisted completion (at baseline) and telephone interview (at follow-up). 
The questionnaire was based on the Client Service Receipt Inventory 
(CSRI)32 and was adapted to take account of the healthcare services likely 
to be used by people with, or at risk of, vision impairment. 
Data collection 
Data were collected at baseline (defined as the day of the clinic but 
before the patient consultations) and at one and three months after 
baseline. All three PROMs and the resource use questionnaire were 
completed by patients in the presence of a researcher in the clinic at 
baseline, and then followed-up by telephone interview at one month and 
three months after the clinic visit. Paper questionnaires were 
administered face-to-face by one of the research team when the patient 
attended the genetics clinic, but prior to being seen by a clinician. All 
written materials were made available in large-print format to promote the 
inclusion of people with visual impairment.  
Statistical analysis 
The fidelity of the standardised care model was assessed by quantifying 
the average time spent by clinicians delivering each of the six defined 
elements. The feasibility of the PROMs was assessed by identifying 
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ceiling/floor effects and the completion rates for each questionnaire. 
Descriptive analyses of average PROM scores and costs at the three time 
points were also undertaken. Changes in PROM scores at the three-month 
follow-up were calculated with 95% confidence intervals and standard 
errors to enable power calculations for a future study, although some 
authors have cautioned against the use of pilot studies to inform power 
calculations.33 All statistical output was produced using Stata (V.13.1, 
StataCorp, College Station, Texas, USA). 
A ceiling effect is observed when a considerable proportion of subjects 
respond with the highest possible score for a given measure.34 A floor 
effect is observed when a considerable proportion of subjects respond with 
the lowest possible score for a given measure.34 Ceiling/floor effects mean 
that the measure is unable to show improvements/declines in patient 
outcomes at the extremes of the measureŨs scale. We looked at the 
proportion of responses with the lowest and highest possible scores for 
each measure. We compared these proportions to a commonly used threshold 
(15% of responses)35 to confirm or deny the presence of ceiling/floor 
effects.  
Each PROM was analysed in accordance with standard practice for the 
individual measure. GCOS-24 questions that were marked as not applicable 
(NA) were recoded to the neutral response (4), as per the instructions at 
the top of the questionnaire. To ensure that 7 indicated the best scenario 
and 1 indicated the worst, responses to questions 4, 5, 10-13, 17, 18, 21 
and 22 were reversed. GCOS-24 scores were calculated as the sum of the 
responses. Each ICECAP-A response has a corresponding value in a published 
UK tariff and ICECAP-A scores were generated by the summation of these 
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values.27 For the EQ-5D, each individual was assigned a score of 1, and 
then the UK tariff set of decrements were applied for domains where 
respondents indicated they had problems.31  
The appropriate study population may not include patients who already had 
some history of care from the genetic eye clinic at baseline. Therefore, 
our analysis of PROM scores considered all patients collectively, as well 
as a pre-defined sub-group analysis of patients who were new to the 
service at baseline. 
Average PROM scores were calculated using both complete-case (CC) analysis 
and multiple imputation (MI). CC analysis only includes patients with 
complete data at all time points for a given PROM. MI is a technique to 
impute missing data and is widely advocated as an improvement over CC 
analysis, as it makes use of available data which would otherwise be 
discarded and is considered to be less biased when data is missing at 
random.36 Mann-Whitney U tests confirmed that baseline PROM scores did not 
significantly differ between patients who had missing data at follow-ups 
and those who did not. MI was conducted in order to reflect the methods 
which would be used in the future study analysis. For imputation, PROM 
scores at each follow-up were modelled by linear regressions with the 
following variables: baseline score (for the respective measure), age, sex, 
and travel time to clinic. To impute missing GCOS-24 scores at baseline, 
the baseline score was not used as an independent variable in the 
regression. The number of imputations were sufficient if they were greater 
than 100 * the largest fraction of missing information (FMI), an accepted 
ŧrule of thumbŨ for multiple imputation.37 Final estimates were the means 
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of the imputed datasets. RubinŨs rules were applied to correct the 
measures of uncertainty.  
Aggregated resource use data were combined with unit costs to find average 
resource use at each time point. Unit costs for NHS services were obtained 
from published NHS reference costs38 and the Personal Social Services 
Research Unit (PSSRU) unit costs of health and social care.39  
 
RESULTS 
Patient characteristics 
104 potential study participants were approached at baseline, of which 6 
patients chose not to participate because they did not wish to complete 
questionnaires. A total of 98 patients received the standardised care 
model and consented to participation in the study. The mean age was 43.6 
years, and 58 women and 40 men were recruited. At baseline, 46 patients 
were classified as ŧnew patientsŨ accessing the service for the first time. 
Baseline patient characteristics and data pertaining to the feasibility of 
using each PROM are presented in Table 1.  
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Table 1 Patient characteristics and feasibility information for PROMs (n = 98) 
 Baseline 1 month 3 months  
Patient characteristics    
     Age, mean 43.6   
     Female 59 (60)    
     New patients 46 (47)   
Missing PROMs data    
     GCOS-24  12 (12) 37 (38) 33 (34) 
     ICECAP-A 0 (0) 32 (33) 33 (34) 
     EQ-5D  0 (0) 32 (33) 33 (34) 
Responses at highest possible score    
     GCOS-24 0 (0) 0 (0) 0 (0) 
     ICECAP-A 14 (14) 7 (11) 9 (13) 
     EQ-5D 33 (34) 15 (23) 20 (31) 
Responses at lowest possible score    
     GCOS-24 0 (0) 0 (0) 0 (0) 
     ICECAP-A 0 (0) 0 (0) 0 (0) 
     EQ-5D 0 (0) 0 (0) 0 (0) 
Data are n (%) unless otherwise specified. 
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Table 2 Changes in average PROM scores (n = 98)   
 Baseline 1 month  3 months  Change from 
baseline 
95% confidence 
interval 
Standard 
error 
Complete cases – all patients        
     GCOS-24a (n = 44) 109.5 112.9 115.2 5.7 2.2; 9.3 1.8 
     ICECAP-Ab (n = 51) 0.827 0.779 0.808 - 0.018 - 0.050; 0.013 0.016 
     EQ-5Dc (n = 51) 0.747 0.744 0.794  0.046 - 0.009; 0.102 0.028 
Multiple imputation – all patients       
     GCOS-24 (n = 98) 107.2 112.3 112.4 5.1 1.4; 8.9 1.9 
     ICECAP-A (n = 98) 0.816 0.794 0.803 - 0.012 - 0.040; 0.016 0.014 
     EQ-5D (n = 98) 0.778 0.776 0.810 0.032 - 0.012; 0.076 0.022 
Complete cases – new patients      
     GCOS-24 (n = 17) 109.5 110.0 115.2 5.7 - 0.3; 11.8 2.9 
     ICECAP-A (n = 20) 0.802 0.782 0.811 0.009 - 0.022; 0.040 0.015 
     EQ-5D (n = 20) 0.784 0.825 0.825  0.040 - 0.033; 0.114 0.035 
Multiple imputation – new patients      
     GCOS-24 (n = 46) 105.8 109.9 111.6 5.9 0.5; 11.1 2.6 
     ICECAP-A (n = 46) 0.820 0.813 0.822 0.002 - 0.036; 0.041 0.018 
     EQ-5D (n = 46) 0.815 0.829 0.845 0.030 - 0.039; 0.101 0.030 
aGCOS-24 feasible range: 24 to 168; bICECAP-A feasible range: 0 to 1; cEQ-5D feasible range: -0.594 to 1. Higher scores preferable. 
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Patient reported outcomes 
To assess the feasibility of using each PROM to quantify the impact of the 
care model, we explored rates of missingness, ceiling/floor effects, and 
changes in PROM scores over time.   
Table 1 shows that the rates of missingness at 1 and 3 months were 38% and 
34% respectively for the GCOS-24. GCOS-24 data was also missing for 12 
patients at baseline because patients did not complete at least one 
question. Some patients stated that GCOS-ɩɫ items were ŧnot applicableŨ 
(NA) to them. To facilitate analysis these items were recoded to the 
neutral response to comply with the instructions of the questionnaire. 
Table S1 shows how many GCOS-24 questions were considered as NA by 
patients. Questions were often marked as NA if they related to the impact 
on the patientŨs children or future children ſQɪ, Qɨɪ, Qɨɮ, Qɨɰ, Qɩɨ and 
Q24). Other questions that were NA related to knowledge about available 
options, and the ability to explain oneŨs condition to others and at risk 
family members (Q10, Q15, Q16 and Q18). 
The rates of missingness for the ICECAP-A and EQ-5D were equal, and were 
33% and 34% at 1 and 3 months respectively. There were no commonly missed 
items in the ICECAP-A or EQ-5D, as the questionnaires were either fully 
completed or not at all for these measures. Data were missing in these 
measures because patients were either not contactable or did not want to 
complete PROMs at a given follow-up. 
No respondents gave the highest possible score for the GCOS-24, and no 
respondents reported the lowest possible score for any of the three 
measures. 
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The ceiling effect threshold of 15% was not met for the ICECAP-A at any 
time-point, however there were still considerable amounts of responses 
with the highest possible score (14% at baseline, 11% at 1 month, and 13% 
at 3 months).  
The proportion of EQ-5D responses at the highest possible score exceeded 
the specified threshold to confirm the presence of ceiling effects at all 
three time points (34% at baseline, 23% at 1 month, and 31% at 3 months). 
This meant that the EQ-5D was unable to detect potential improvements in 
health status from baseline for 34% of the sample. 
While ceiling effects in a measure indicate that an individualŨs responses 
to every domain were simultaneously at the highest scoring level, it was 
also of interest to investigate which domains were most commonly scored at 
the highest level by respondents. Further investigation found that the EQ-
5D domain to which respondents most frequently indicated having no 
problems was ŧself-careŨ ſɯ0% of respondents at baseline, complete case). 
Similarly the ICECAP-A domain to which respondents most frequently 
indicated having the highest capability was ŧattachmentŨ ſɭɫ% of 
respondents at baseline, complete caseƀ, which considers the individualŨs 
ability to have love, friendship, and support. 
Table 2 presents average PROM scores at each time point for all patients 
(n = 98) and new patients (n = 46), as results of complete case (CC) and 
multiple imputation (MI) analysis. The study was inadequately powered to 
conclude, using measures of statistical significance, that the scores of 
the measures had improved by the 3 month follow-up. However, a trend 
towards improvement was seen for all three measures. The distributions of 
PROMs at all time-points are provided in Figure S1. 
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Fidelity 
76 patient checklists were completed, which represented 78% of the total 
patient sample. Follow-up plans were recorded for 59 patients (78% of 
completed checklists). Table 3 shows the time healthcare professionals 
spent delivering the service. Average times are reported as medians with 
interquartile ranges to account for the skewed nature of the data. 
Discussion points in the care model were not always addressed, although 
clinicians were permitted to be flexible in tailoring discussions to the 
needs of the patient. All elements were used across the consultations, and 
it was demonstrated that the entire range could be delivered by a team of 
professionals within a single consultation. 
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Table 3 Fidelity of the care model assessed by the checklist (n = 76) 
Discussion point Median time spent 
on discussion 
(minutes) 
Interquartile 
range 
Discussion point 
addressed, n (%)  
Diagnosis & management  10 10; 18 73 (96) 
Clinical information 10 5; 10 69 (91) 
Research information 2 0; 5 42 (55) 
Decision making 5 0; 10 51 (67) 
Counselling & communication 5 0; 5 49 (64) 
Practical support 2 0; 5 47 (62) 
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Videos of appointments (n = 10) showed that clinicians adhered to the care 
model and accurately recorded what was delivered on the checklist.  
Resource use 
Table S2 shows the types of resources used, consistent with taking an NHS 
perspective, over the month prior to completion of the questionnaire. 
Average usage, and therefore average cost, of accessing community and 
hospital-based NHS services fell for patients affected by IRD after 
receiving the care model. A complete list of non-NHS services accessed by 
patients is provided in Table S3. 
DISCUSSION 
The delivery of genomic counselling and testing within routine mainstream 
clinical care represents a considerable challenge. This study has assessed 
the fidelity of delivering a standardised care model for patients with IRD 
and the feasibility of using the selected PROMs and resource use 
questionnaire to quantify its impact. A checklist that asked clinicians to 
capture the elements of the standardised care model they delivered 
indicated that it could be delivered in a consistent way. This suggests 
that it is feasible to take this standardised care model forward and that 
it may be possible to assess its impact in a future substantive, 
prospective study.   
The ICECAP-A was identified as a potentially useful measure of the impact 
of the care model. This was because the ICECAP-A had fewer missing 
responses than the GCOS-24 and had fewer responses with the highest 
possible score at baseline than the EQ-5D. While the GCOS-24 was 
specifically designed for use in the context of a clinical genetics 
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service,24 this study found that GCOS-24 completion rates were lower than 
the ICECAP-A and EQ-5D, and that questions involving reproductive choices 
and children were often considered not relevant by study participants. A 
study using qualitative methods would be useful to understand the reasons 
behind this, particularly if answering NA was used as a way to ŧopt-outŨ 
because the questions caused concern or worry to the patient. The measure 
comprises 24 questions which may also have been problematic in a 
population of visually impaired individuals. Further research is suggested 
to explore whether a shortened version of the GCOS-24 would be more suited 
to use in the context of a trial for patients with IRD. This would require 
re-validation of the short form version. 
As the EQ-5D displayed considerable ceiling effects, further empirical 
work is needed to determine whether it is suitable for use in populations 
with genetic eye conditions. A 5-level version of the EQ-5D has recently 
been developed to address criticisms regarding responsiveness and ceiling 
effects.40 The 5-level version could potentially offer improvements over 
the 3-level version used in this study. One benefit of the EQ-5D is that, 
due to its generic nature, it enables comparisons across populations and 
health conditions. While it is unclear whether the 3-level EQ-5D is an 
appropriate measure to capture the effects of a genomic care model, having 
the data enables these comparisons. 
There were decreases in average ICECAP-A scores after one month, followed 
by increases after 3 months. While the study was not sufficiently powered 
to assess these changes in terms of statistical significance, the results 
suggest that benefits of the care model may only accrue after a longer 
time period. This demonstrates the importance of choosing a suitable time-
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horizon, especially when the intervention may have delayed benefits 
because of the need for patients to adjust to the diagnosis of an 
inherited condition.19  
To assess fidelity, checklists were completed by the clinicians who 
delivered the intervention. There was no incentive for an individual 
clinician to falsify the checklist as they were used to guide the next 
clinician who saw the patient in the clinic. This method also ensured that 
clinicians were reminded of the key deliverables of the care model. Our 
analysis showed that discussion points in the care model were not always 
addressed. This was not a pressing concern since clinicians were permitted 
to be flexible in tailoring discussions to the needs of the patient. 
However, it may have been useful to define minimum acceptable thresholds a 
priori for the delivery of each discussion point, so that clinicians were 
aware of the importance of each element of the care model and to confirm 
fidelity. Fidelity was also assessed in video format by independent 
observers. While being recorded, it is possible that clinicians altered 
their behaviour in anticipation of being evaluated. This bias (often 
referred to as the Hawthorne effect) could be introduced whenever 
clinicians are observed, yet it was necessary to use an observer to 
confirm that fidelity was recorded accurately. 
A further potential limitation of the study was that, despite the pre-post 
design, patients were recruited at baseline regardless of whether or not 
they were new to the service. This meant that some patients had previously 
accessed elements of the care model. Baseline results were therefore 
confounded by previous visits and may not allow for an accurate 
representation of the true effects of the care model. To capture the long 
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term benefits of the care model, where patients would start to receive the 
care model on their first visit, the recruitment of only new patients to a 
future study would be appropriate. 
The care model was only delivered in one centre which may raise concerns 
over the external validity of the results. It is also possible that 
clinical geneticists could perform the same role as genetic counsellors in 
the delivery of the care model. By providing other centres with the care 
model in a replicable (manualised) format, it is expected that future 
results would be similar elsewhere. 
In conclusion, this study provides evidence to support the fidelity of a 
standardised care model for patients with IRD in one centre. It is 
suggested that a future study should only recruit new patients to identify 
the impact of the new model of care. The ICECAP-A was shown to be 
potentially useful in this context. A genetics service specific measure 
was found to require some adaptation for use in a future study. The key 
items of resource use from the NHS perspective were identified. A larger 
sample size would be required to detect statistically significant changes 
in a definitive study. The relevant follow-up period for a study assessing 
the impact of a care model that focusses on achieving a genetic-based 
diagnosis should be sufficiently long and at least three months. The 
findings from this study can be used to inform the design of a future 
definitive study to assess the clinical and cost-effectiveness of a 
standardised care model for IRD within the context of mainstream 
ophthalmic care.  
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FIGURE LEGENDS 
Figure 1   A service flow of the integrated care model for inherited 
retinal dystrophies 
 
<Figure 1> 
 
Figure 2   Provision of the integrated care model for inherited retinal 
dystrophies 
 
<Figure 2> 
 
aIncluding examination, OCT, ERGs. bIncluding information on treatment and 
management. 
CVI, Certificate of Vision Impairment; ERG, Electroretinogram; OCT, Optical 
Coherence Tomography; PIP, Personal Independence Payment; VI, Visual Impairment 
